MétaCan
Menu
Back to cohort
Record W4416717861 · doi:10.1097/md.0000000000045802

A real-world analysis of Lomitapide-associated adverse events: Data from FAERS and CVAROD

2025· article· en· W4416717861 on OpenAlexaboutno aff
Zhiwen Zheng, Yijia Liu, Shangze Li, Hui Wang

Bibliographic record

VenueMedicine · 2025
Typearticle
Languageen
FieldPharmacology, Toxicology and Pharmaceutics
TopicPharmacovigilance and Adverse Drug Reactions
Canadian institutionsnot available
Fundersnot available
KeywordsAdverse Event Reporting SystemAdverse effectDiarrheaOdds ratioNauseaAbdominal painPharmacovigilanceVomiting

Abstract

fetched live from OpenAlex

Lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor approved for the treatment of Homozygous Familial Hypercholesterolemia (HoFH), effectively lowers LDL cholesterol but raises safety concerns, particularly regarding hepatic and gastrointestinal adverse events (AEs). We conducted a pharmacovigilance disproportionality analysis using 2 major spontaneous reporting systems: the U.S. FDA Adverse Event Reporting System (FAERS, 2004-2024) and the Canada Vigilance Adverse Reaction Online Database (CVAROD, 2014-2025). All Lomitapide-related reports were extracted and analyzed using 4 statistical algorithms: reporting odds ratio (ROR), proportional reporting ratio, information component (IC), and Empirical Bayes Geometric Mean (EBGM). Signals were assessed at both the system organ class (SOC) and preferred term (PT) levels, with clinical priority scoring applied to rank AEs by relevance and impact. A total of 3665 FAERS and 80 CVAROD reports were analyzed. Gastrointestinal events were most frequent, including diarrhea (n = 1072; LBROR = 7.78), weight loss (n = 832; LBROR = 13.44), and nausea (n = 525; LBROR = 2.87). Hepatic events included elevated liver enzymes (n = 190; LBROR = 11.47) and hepatic steatosis (n = 67; LBROR = 13.01). Metabolic complications such as increased LDL levels (n = 159; LBROR = 85.45) were also observed. Subgroup analyses indicated higher susceptibility in males for diarrhea and weight loss, and in minors for abdominal pain (n = 10; LBROR = 7.53) and vomiting (n = 6; LBROR = 1.96). Novel signals, including renal pain (n = 10; LBROR = 2.33) and intestinal hemorrhage (n = 3; LBROR = 1.98), were identified, previously unreported in clinical trials. Most AEs occurred within the first week of treatment. Lomitapide is associated with clinically significant gastrointestinal, hepatic, and metabolic AEs, with elevated risk in male and pediatric patients. The early onset of reactions and emergence of novel signals highlight the importance of close monitoring, particularly during treatment initiation. Personalized risk mitigation strategies should be implemented to optimize the safety of Lomitapide therapy in HoFH patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.017
metaresearch head score (Gemma)0.062
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.017
Threshold uncertainty score0.091

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0170.062
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0050.007
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.157
GPT teacher head0.496
Teacher spread0.339 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueMedicineSame topicPharmacovigilance and Adverse Drug ReactionsFrench-language works237,207